Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Flotufolastat F 18

Phase 2Small molecule

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

PET/CTActive, not recruiting

PET/CTPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q4 2032

Phase 2Active, not recruiting

PET/CT

NCT07220720

Clinical

Trials by Indication[1]

PET/CT1 trial

POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

Active, not recruiting·UUniversity of Florida·Phase 2·NCT07220720·30 enrolled

ART1 trial

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

Withdrawn· Novartis logo

Novartis·Phase 1/2·NCT06881823

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Flotufolastat F 18. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Flotufolastat F 18 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Flotufolastat F 18. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

Related News